Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
12.72
-0.22 (-1.70%)
Aug 5, 2026, 3:11 PM EDT - Market open
Omeros Employees
Omeros had 175 employees as of December 31, 2025. The number of employees decreased by 27 or -13.37% compared to the previous year.
Employees
175
Change (1Y)
-27
Growth (1Y)
-13.37%
Revenue / Employee
$56,531
Profits / Employee
$492,400
Market Cap
920.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 175 | -27 | -13.37% |
| Dec 31, 2024 | 202 | 4 | 2.02% |
| Dec 31, 2023 | 198 | 2 | 1.02% |
| Dec 31, 2022 | 196 | -17 | -7.98% |
| Dec 31, 2021 | 213 | -64 | -23.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 465 |
| Geron | 258 |
| EyePoint | 214 |
| Sana Biotechnology | 142 |
| Janux Therapeutics | 108 |
| Odyssey Therapeutics | 100 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
OMER News
- 2 days ago - Omeros grants new technology add-on payment status to Yartemlea - TheFly
- 2 days ago - CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® - Business Wire
- 9 days ago - AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright - TheFly
- 9 days ago - Omeros up 11% to $10.89 after AstraZeneca study failure - TheFly
- 23 days ago - Omeros Corporation Investigated by the Portnoy Law Firm - GlobeNewsWire
- 5 weeks ago - Omeros stock crashes on regulatory setback: buy the dip? - Invezz
- 5 weeks ago - Omeros price target lowered to $33 from $40 at H.C. Wainwright - TheFly
- 5 weeks ago - Omeros announces CHMP adopts negative opinion on MAA for narsoplimab - TheFly